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Abstract 
The capability to expand human bone marrow mononuclear cells (BM MNC) in high density perfusion cul- 
ture chambers (bioreactors) has recently been developed. In these bioreactors, total cell colony-forming unit- 
granulocyte/macrophage (CFU-GM), and long-term culture-initiating cell (LTC-IC) numbers increase significantly 
over a 14-day period. However, cell growth ceases after the 14-day period, possibly due to cell density limitations. 
Because of the remaining presence of early cells, it should be feasible to replate the cells and obtain continued 
expansion. In this study, we demonstrate that bioreactors generate cells, which upon replating into secondary biore- 
actors, lead to continued cell, CFU-GM, and LTC-IC8 (measured after 8 weeks of secondary culture) expansion. A 
two-stage protocol, involving the replating of cells on days 9 to 12 of culture into new bioreactors at the original 
seeding density, yielded greater than 50-fold cell expansion from BM MNC in 25 days. CFU-GM were expanded 
11- to 12-fold and LTC-IC8 numbers increased 6.3-fold over the same 25-day period. The addition of leukemia 
inhibitory factor (LIF) had no significant effect on total cells, CFU-GM, or LTC-IC5 in this system. We conclude 
that two-stage bioreactor cultures are capable of supporting extended growth of human BM MNC, CFU-GM, and 
LTC-ICs. The continued expansion of these primitive cells in the second stage of culture suggests that primitive 
cells with significant proliferative potential were generated in this system, and previous data on LTC-IC5 expansion 
has now been extended to LTC-IC8 expansion. Further optimization of culture conditions is likely to improve on 
the results obtained here, thus making perfusion bioreactor culture correspondingly more attractive for expanding 
BM MNC for BM transplantation. 
Introduction 
In recent years, considerable interest has been focused 
on the expansion of human hematopoietic cells ex vivo 
(e.g. see Koller and Palsson, 1993). Successful culture 
systems would enable a variety of basic scientific and 
clinical studies in the fields of hematopoiesis and bone 
marrow (BM) transplantation. One attractive approach 
to accomplish this goal is the bioreactor culture of a 
small amount of aspirated BM resulting in expansion of 
total cell, CFU-GM, and LTC-IC numbers (Palsson et 
al., 1993; Koller etal., 1993). However, although these 
cultures generate significant numbers of cells after 14 
days, the cell density reaches a plateau and little cell 
growth is obtained thereafter. Therefore, it appears that 
growth is limited by the cell density which can be sup- 
ported by the current bioreactor design. Because the 
cells at that time contain primitive cells, it should be 
feasible to obtain further cell growth by removing some 
of the cells periodically, or by replating the cells onto a 
larger surface area (i.e. into many secondary bioreac- 
tors). Although periodic removal of cells has met with 
some degree of success (Oh et al., 1994), multiple 
disruptions of the cell bed is most likely undesirable 
in any clinical application. Therefore, one complete 
optimally-timed harvest and replating of all cells from 
the system might result in a more robust stimulus for 
growth, and may be more desirable in clinical prac- 
tice. 
126 
Replating of cultured hematopoietic cells into sec- 
ondary cultures has been used as an indication of the 
primitive nature or self-renewal potential of cells (Ter- 
stappen et al., 1991; Carow et al., 1993). These types 
of experiments have been more successful with cord 
blood than with adult BM, suggesting that fewer cells 
in adult BM have self-renewal potential (Carow et al., 
1993). These results have been confirmed and extended 
using primitive cell sorting, demonstrating that human 
fetal liver contains cells which are most proliferative 
upon replating, and that adult BM has a relatively low 
self-renewal potential (Lansdorp et al., 1993). There- 
fore, replating of bioreactor expanded adult BM should 
yield valuable information on the self-renewal poten- 
tial of the cells which are generated under these condi- 
tions. 
One factor which has recently been shown to affect 
primitive cell self-renewal is leukemia inhibitory fac- 
tor (LIF). Several studies have suggested that in vivo 
repopulating murine cells are better maintained in the 
presence of LIF (Fletcher et al., 1991; Escary et al., 
1993). In contrast, in vitro studies of purified human 
hematopoietic cells have shown a less dramatic effect 
of LIF (Verfaillie and McGlave, 1991; Brugger et al., 
1993; Debili et al., 1993). Because LTC-IC analysis of 
two-stage bioreactor cultures offers a model to study 
primitive human cell self-renewal, we have also exam- 
ined the effect of exogenous LIF in these studies, 
Materials and methods 
Cells Human BM was obtained from heparinized 
aspirates from the iliac crest of informed and con- 
senting individuals. BM was separated by a Ficoll- 
Paque (Pharmacia, Uppsala, Sweden) density gradient 
centrifugation, and the low density MNC in the inter- 
face band were collected and washed three times with 
Iscove's modified Dulbecco's medium (IMDM, GIB- 
CO, Grand Island, NY) as previously described (Koller 
et al., 1993). 
Culture medium and hematopoietic growth factors 
The culture medium was IMDM containing 10% fetal 
bovine serum, 10% horse serum (Gibco), 1% peni- 
cillin/streptomycin (10,000 U m1-1 penicillin G and 
10 mg m1-1 streptomycin), and 36 mM sodium bicar- 
bonate (Sigma, St. Louis, MO). Culture medium 
was supplemented with four growth factors: 2 ng 
m1-1 interleukin-3 (IL-3, R & D Systems, Minneapo- 
lis, MN), 5 ng m1-1 granulocyte-macrophage colony- 
stimulating factor (GM-CSF, Immunex, Seattle, WA), 
0.1 U m1-1 erythropoietin (Epo, Amgen, Thousand 
Oaks, CA), and 10 ng m1-1 stem cell factor (SCF, c-kit 
ligand, Genzyme, Cambridge, MA). In one experi- 
ment, 5 ng ml-1 leukemia inhibitory factor (LIF, R&D 
Systems) was added to the medium. 
Bioreactor system and replating The bioreactor sys- 
tem used was comprised of a small cell culture cham- 
ber with continuous flow of medium as previously 
described (Palsson et al., 1993). In the first set of 
experiments, each of six bioreactors was inoculated 
with 4 • 106 BM MNC. Three bioreactors were har- 
vested on both days 10 and 12. Harvested cells were 
counted and assayed for CFU-GM and LTC-IC. Cells 
from the three individual bioreactors were pooled and 
re-inoculated into ten new bioreactors at a cell density 
of 4 x 106 cells each. Two bioreactors, chosen random- 
ly from the ten secondary bioreactors, were harvested 
every two days and cells were counted and analyzed 
for CFU-GM and LTC-IC. 
In a second experiment, of nine reactors inoculated, 
six were harvested on day 9 (3 with and 3 without LIF) 
and three on day 11 (without LIF). The harvested cells 
from days 9 and 11 were replated into ten bioreactors 
as described above to measure extended growth. In 
addition, two sets of one-stage expansion controls were 
analyzed (six bioreactors). Six bioreactors (three with 
and three without LIF) were terminated on day 14. 
None of the control cultures were replated. 
Cell harvest and colony assay Nonadherent ceils 
were collected with a syringe by aspirating the medi- 
um contained in the bioreactor, which was followed 
by two washes of Hank's balanced saline solution 
(HBSS, GIBCO). Adherent cells were harvested by 
subsequent trypsinization for 20 min, followed by a 
wash with medium. MNC were counted by an elec- 
tronic cell counter (Coulter Electronics, Hialeah, FL) 
using a filtered aqueous solution containing 30 g 1-1 
hexadecyl tri-methylammonium bromide (cetrimide, 
Sigma), 0.37 g 1-1 ethylenediaminetetraacetic acid 
(EDTA, Sigma), and 8.3 g 1-1 NaCI. CFU-GM den- 
sity in the inoculated and harvested cell populations 
was enumerated with a two week colony assay. Ceils 
from different nonadherent and adherent cell popula- 
tions were suspended separately at a cell density of 2 
• 104 cells/ml in methylcellulose medium (Terry Fox 
Labs, Vancouver, Canada) containing 2 U ml -I  Epo, 2 
ng m1-1 IL-3, 5 ng m1-1 GM-CSF, and 5 ng m1-1 gran- 
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Fig. 1. Growth of human BM MNC in a two-stage perfusion bioreactor expansion culture. (a) Cells from first-stage bioreactors (open circles) 
were replated at days 10 (closed circles) and 12 (closed squares) into ten new bioreactors, and these were harvested at two to three day intervals 
thereafter. (b) Total cell numbers obtainable from the initial 4 million cell inoculum were calculated by adjusting for the cell split at the day of 
replating. The arrows indicate the time of replating. 
Amgen). After 14 days in a humidified 5% 02 and 5% 
CO2 incubator, colonies of greater than 50 cells were 
scored. 
Long-term culture-initiating cell (LTC-IC) assay For 
enumeration of LTC-IC in the inoculated and harvest- 
ed cell populations, limiting dilution assay (LDA) was 
used (Sutherland et al., 1990) as previously described 
(Koller et al., 1993). LTC-IC cultures were carried for 
either five (LTC-ICs) or eight weeks (LTC-ICs). LTC- 
IC8 are thought to be more primitive than LTC-IC5 
because they are less frequent in marrow (Sutherland 
et al., 1990) and appear to be more resistant to 4-HC 
(Winton and Colenda, 1987). Cells were plated on 
irradiated stromal layers at concentrations from 1 to 
5 • 104 cells per well in a 96-well culture plate (20 
replicates per concentration). The plates were placed 
in a fully humidified 33 ~ 5% C Q  incubator, and 
the cultures were fed weekly by replacing 50% of the 
medium. After either five or eight weeks of culture, 
cells were harvested from each well by trypsiniza- 
tion, then washed with HBSS and added to 0.25 ml 
of colony assay medium in 24-well plates. Colonies 
were scored by the colony assay protocol described 
above. For each sample, the number of LTC-IC was 
determined through an iterative calculation procedure 
(De St. Groth, 1982) based on the maximum like- 
lihood method (Finney, 1951), Confidence intervals 
were calculated as described (De St. Groth, 1982) and 
are shown on Figs. 3 and 6. 
Results 
Two-stage expansion of bone marrow in bioreactors 
Six bioreactors were inoculated with 4 million BM 
MNC each. Three bioreactors were harvested on days 
10 and 12, and at both times, cells were pooled and 
inoculated into ten new bioreactors at 4 million cells 
each. Cells in excess of the 40 million required to inoc- 
ulate the ten bioreactors were discarded. During the 
second expansion period, two bioreactors were har- 
vested every two days to generate the extended growth 
curve. In the first stage, the cells expanded approxi- 
mately 5- and 6-fold by days 10 and 12, respectively 
(Fig. 1 a). After replating, the cells continued to expand, 
reaching over 25 million cells per bioreactor at the last 
time point examined. If all ten of the bioreactors used 
during the second expansion period had been harvest- 
ed on the last day, the overall cell expansion would 
have been 30-fold (10 day series) and 40-fold (12 day 
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Fig. 2. The number of CFU-GM produced in a two-stage perfu- 
sion bioreactor expansion culture. Experimental conditions are as in 
Fig. 1. Total CFU-GM numbers obtainable from the initial 4 million 
cell inoculum were calculated by adjusting for the cell split at the 
day of replating. The arrows indicate the time of replating. Circles 
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Fig. 3. The number of  LTC-IC8 produced in a two-stage perfu- 
sion bioreactor expansion culture. Experimental conditions are as in 
Fig. 1. Total LTC-IC8 numbers obtainable from the initial 4 million 
cell inoculum were calculated be adjusting for the cell split at the day 
of replating. The arrow indicates the time of replating. Dashed lines 
correspond to a 95% confidence interval based on the maximum 
likelihood solution method [15]. 
series). This observation, which adjusts for the cell 
split on the day of replating, is reflected in Fig. lb. 
The number of CFU-GM (per 4 million cells initial- 
ly inoculated) increased until day 10 to give a 5.1-fold 
expansion (Fig. 2). After replating on day 10, CFU-GM 
numbers increased further to give a 9.7-fold expansion 
by day 12, but then declined on days 14 and 16. In a 
similar fashion, after replating on day 12, CFU-GM 
numbers increased further to give a 7.3-fold expansion 
by day 14, but then declined on day 16. After day 
16, CFU-GM numbers increased dramatically in both 
groups, resulting ultimately in a greater than 14-fold 
expansion of CFU-GM. 
In this experiment, the number of primitive LTC- 
IC8 were enumerated at several time points of the 
day 12 series (Fig. 3). LTC-IC8 were expanded 2-fold 
by day 12 of culture. After replating, LTC-IC8 num- 
bers continued to increase, resulting in a total 6.3-fold 
expansion (p < 0.05) over the two-stage culture peri- 
od. 
Effect of exogenous LIF on two-stage bioreactor cul- 
tures In the second series of experiments, cells were 
replated as described above, except in three experi- 
mental groups; two at day 9 and one at day 11. One 
of the two day 9 groups contained LIF in addition 
to the standard four growth factors (IL-3, GM-CSF, 
SCF, and Epo). In addition to the experimental groups 
that were replated, triplicate control one-stage cultures 
were examined at day 14 (with and without LIF) as 
points of reference. Cell expansion was similar to that 
obtained in the first series of experiments (Fig. 4a). The 
one-stage controls generated about 42 million cells per 
bioreactor by day 14. All two-stage cultures expanded 
cells before and after replating, resulting in approxi- 
mately 30 million cells per bioreactor at the last time 
point examined. The extended growth curve, adjusted 
for the cell split at replating, shows that greater cell 
expansion was obtained in two-stage cultures than in 
one-stage cultures (Fig. 4b). For example, one-stage 
cultures generated 10.5-fold cell expansion by day 14 
(open triangles, Fig. 4b), whereas two-stage cultures 
resulted in 40-fold cell expansion at day 21 and nearly 
60-fold by day 27. The increase in cell growth area pro- 
vided by the replating procedure thus allowed the cells 
to continue expanding beyond the limitations imposed 
by the one-stage expansion protocol. There did not 
appear to be a significant effect of exogenous LIF on 
the cell expansion data. 
CFU-GM numbers, adjusted for the cell split at 
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Fig. 4. Effect of LIF on the growth of human BM MNC in a two-stage perfusion bioreact0r expansion culture. (a) Cells from first-stage 
bioreactors were replated at days 9 (circles) and 11 (squares) into ten new bioreactors, and these were harvested at two to three day intervals 
thereafter. Bioreactors with LIF were also examined with the day 9 replating protocol (open circles). Control one-stage bioreactors were 
examined at day 14 with and without LIF (small solid and open triangles, respectively). (b) Total cell numbers obtainable from the initial 4 
million cell inoculum were calculated by adjusting for the cell split at the day of replating. The arrows indicate the day of replating. 
Fig. 5. 
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two-stage bioreactor expansion. Experimental conditions and sym- 
bols are as in Fig. 4. Total CFU-GM numbers obtainable from the 
initial 4 million cell inoculum were calculated by adjusting for the 
cell split at the day of replating. The arrows indicate the time of 
repluting. 
experiment (Fig. 5). CFU-GM numbers increased until 
day 12, then declined briefly several days after replat- 
ing, and then continued increasing at later time points. 
Although the number of CFU-GM obtained on day 14 
was similar in the one- and two-stage cultures, two- 
stage cultures continued to expand CFU-GM numbers 
beyond day 14, whereas one-stage cultures typical- 
ly exhibit a decline in CFU-GM numbers following 
day 14 (e.g. see Palsson et al., 1993). This demon- 
strates that the two-stage expansion protocol allowed 
expansion of progenitors beyond the cell growth area 
limitations imposed by the one-stage expansion proto- 
col. 
LTC-IC5 were enumerated in the inoculum and at 
the time of replating (Fig. 6). Unfortunately, LTC-IC 
data were not obtained during the second expansion 
stage9 LTC-IC5 expanded 2- to 3-fold during the first 
9 to 11 days of culture, which is consistent with the 
data presented above and our previously published data 
(Keller et al., 1993)9 LIF did not significantly increase 
the number of LTC-iC5 generated by day 9. 
Discussion 
High cell density bioreactor cultures of BM MNC have 
demonstrated the expansion of total cell, CFU-GM, 
and LTC-IC5 numbers over a 14-day cultivation peri- 
od (Palsson et al., 1993; Keller et at., 1993). How- 








2 4 6 8 10 12 
Time (day) 
Fig. 6. Effect of LIF on the number of LTC-IC5 produced in 
a perfusion bioreactor expansion system. Experimental conditions 
and symbols are as in Fig. 4. 
days and little additional growth is obtained thereafter. 
Because of the remaining presence of early cells, it 
should be feasible to replate the cells and obtain con- 
tinued expansion. In this study, we demonstrate that 
bioreactor cultures generate cells, which upon replat- 
ing into secondary bioreactors, lead to continued cell, 
CFU-GM, and LTC-IC8 expansion. In addition, we 
demonstrate that the addition of exogenous LIF at 5 ng 
ml - l  to the other four growth factors used (IL-3, GM- 
CSF, SCF, and Epo) did not have a significant effect 
on the cell parameters measured in this study. 
The results obtained through the single replating 
procedure further demonstrate that bioreactor cultures 
are capable of retaining early cells while expanding 
their progeny. Significant increases in both total cells 
and CFU-GM were obtained in the two-stage cultures 
as compared with the one-stage cultures. The LTC- 
IC5 expansion results after the first stage of culture are 
consistent with our earlier published results (Koller et 
al., 1993). Because LTC-IC8 are thought to be more 
primitive than LTC-IC5 (Sutherland et al., 1990; Win- 
ton and Colenda, 1987), the LTC-IC8 expansion results 
extend the earlier expansion results to a more primi- 
tive cell type. Furthermore, the continued expansion of 
these primitive cells in the second stage of culture sug- 
gests that primitive cells with significant proliferative 
potential were generated in this system. It is interest- 
ing that the number of LTC-IC8 did not increase until 
after day 8, whereas LTC-IC5 appeared to increase 
earlier. One possible interpretation of these data is that 
a small subset of stem cells were committed to dif- 
ferentiation upon inoculation, followed by some self- 
renewal in that compartment. Upon replating, there 
was an increase in CFU-GM number, followed by a 
decrease, and then another large increase. It appears 
that replating caused activation of early cells which 
required several days to appear in the CFU-GM com- 
partment. This activation, which resulted in a second 
wave of cell growth without loss of primitive cells, did 
not occur without replating. These observations may 
be compared with reports noting that a few days are 
required for stem cells to enter cell cycle after the initi- 
ation of culture. For instance, it has been reported that 
highly purified early cells (CD34 + CD45RA 1~ CD71 l~ 
require 60 h of culture before the first division takes 
place (Denkers et al., 1993). 
The extended growth potential of bioreactor- 
expanded cells has also been demonstrated by fre- 
quent harvesting of a high fraction of non-adherent 
and adherent cells (Oh et al., 1994). When only non- 
adherent cells are removed, the extended expansion of 
progenitor cells is limited. These results are thus con- 
sistent with the observation reported here; that disrup- 
tion of the association between stroma and primitive 
cells, followed by replating at the original cell den- 
sity, results in increased production of all cell types 
over time. One feature of this two-stage protocol is the 
continued growth of autologous stroma in the bioreac- 
tors without attainment of complete confluence. This 
continuously growing stroma may be one factor which 
drives the continuous expansion of LTC-IC. Consistent 
with this concept are reports showing that liquid cul- 
tures of selected CD34 + cells, which do not allow for 
stromal cell growth, do not expand or maintain LTC-IC 
(Sutherland et al., 1991, 1993; Verfaillie, 1992; Koller 
et al., 1995a). 
Our results indicate that exogenous LIF had no sig- 
nificant effect on total cells, CFU-GM, or LTC-IC5 in 
this system. Although previous studies have suggested 
that in vivo repopulating murine cells are better main- 
tained in the presence of LIF (Fletcher et al., 1991; 
Escary et al., 1993), in vitro studies of purified human 
hematopoietic cells have shown a less dramatic effect 
of LIF (Verfaillie and McGlave, 1991; Brugger et al., 
1993; Debili et al., 1993). Because of the presence 
of accessory cells and stroma in these bioreactors, 
endogenous production of LIF may overshadow any 
effects of exogenous LIE In fact, we have evidence 
that LIF is endogenously produced in these cultures, 
al though at re la t ively  low levels  o f  < 50 pg m1-1,  
(Koller  et  al . ,  1995b). 
The  results presented  here  indicate  that perfu-  
s ion bioreactors  support  a l imited number  o f  cells, 
after which  little g rowth  occurs.  A number  o f  fac- 
tors could  l imit  the m a x i m u m  cel l  densi ty  attained in 
these cultures.  One  such factor is s imply the size o f  
the  cell  g rowth  area. Af te r  14 days, the growth  surface 
becomes  comple te ly  covered  with a layer o f  cells at 
least 4--6 cells deep.  This  may  result  in contact  inhi-  
bi t ion o f  certain cel l  types,  or  in nutr ient  or  o x y g e n  
l imita t ion wi th in  the cel l  bed.  These  and other  con-  
siderat ions have  been  discussed e l sewhere  in detai l  
(Kol ler  and Palsson,  1993). It  is therefore  l ikely that 
further  op t imiza t ion  o f  bioreactors  for hematopoie t -  
ic cel l  g rowth  wil l  result  in improved  culture perfor-  
mance.  
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